-
![Bioreactor-GettyImages-801080370]( "The Module Type Package Wants All Your Equipment To Start Talking")
The Module Type Package Wants All Your Equipment To Start TalkingA forthcoming ISPE guide uses case studies to aid in the design of plug-and-play process skids with implications for every step in the manufacturing process continuum.
-
![pharmaceutical manufacturing-GettyImages-2230289877]( "Why Your MVP And Its Evolution Matters To Manufacturing")
Why Your MVP And Its Evolution Matters To ManufacturingMinimum viable product is one of the most important inputs to developing a manufacturing process. It defines essentials that matter to the people who make the product.
-
![BPO-LBP_Concentration_Feature-450x300]( "TFF Offers Ideal Anaerobic, GMP Conditions For LBP Concentration")
TFF Offers Ideal Anaerobic, GMP Conditions For LBP ConcentrationWhen configured correctly, TFF provides the gentle processing environment and oxygen protection required for strict anaerobes.
-
![GettyImages-1309776439-scientists-lab-analysis-manufacturing]( "Speed Meets Precision With Process Development Services")
Speed Meets Precision With Process Development ServicesExplore strategies to accelerate biosimilar development that help manufacturers reduce timelines, optimize workflows, and meet regulatory standards while delivering cost-effective therapies.
-
![Flask Laboratory Equipment-GettyImages-1048897552]( "An End-To-End Automated HTP Platform For Cell Line Optimization")
An End-To-End Automated HTP Platform For Cell Line OptimizationBristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline.
-
![FDA headquarters, white oak campus-GettyImages-1413289936]( "FDA Draft Guidance On CES Signals More Reliance On Toxicity And PK")
FDA Draft Guidance On CES Signals More Reliance On Toxicity And PKThe technology to measure alternative metrics is vastly improved. Now, FDA joins other regulators in deprioritizing comparative efficacy studies for biosimilars.
-
![Bacteriophage Virus Cycle-GettyImages-1784637244]( "Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug Development")
Phages As A Pharmaceutical: New EMA Guidance On Antimicrobial Drug DevelopmentThe EMA has now issued a draft guidance on quality aspects of phage therapy medicinal products. Rising antimicrobial resistance has renewed interest in bacteriophages to fight pathogens.
-
![Futuristic data-GettyImages-1325172964]( "How To Improve Sponsor–CMO Collaboration Around Digital Deviations")
How To Improve Sponsor–CMO Collaboration Around Digital DeviationsDigital strategies and standardized data models cut manual work, boost accuracy and speed of information sharing, and build trust between sponsors and CMOs.
-
![GettyImages-2213157127-drug-formulation-discovery-pipette-liquid-vial]( "How One Biotech Company Is Accelerating The Drug Discovery Workflow")
How One Biotech Company Is Accelerating The Drug Discovery WorkflowSee how biotech innovation is accelerating drug discovery through AI, miniaturized workflows, and collaborative technologies to reshape how therapies are developed and delivered.
-
![mRNA GettyImages-1428646288]( "Advanced Therapies Going Mainstream: Are We There Yet?")
Advanced Therapies Going Mainstream: Are We There Yet?Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.
-
![Virus Retention Performance Under Diverse Processing Conditions]( "Virus Retention Performance Under Diverse Processing Conditions")
Virus Retention Performance Under Diverse Processing ConditionsVirus filtration is robust across a wide range of process parameters, including high protein concentration and flow decay. Discover how retention relies on size exclusion to simplify risk assessment.
-
![Getty Images-823447656-vector-viral-lab-AAV-cell-development]( "Understanding Adeno-Associated Virus Vector Impurities")
Understanding Adeno-Associated Virus Vector ImpuritiesAAV vectors hold promise for gene therapy, but removing product-related impurities remains a challenge. Learn how cell line development and process optimization are advancing rAAV production.
-
![GettyImages-1590576166 cells, research, lab, assay]( "Cell Culture Media Demystified For Performance, Quality, And Innovation")
Cell Culture Media Demystified For Performance, Quality, And InnovationCell culture media isn’t one-size-fits-all. Learn how media composition, customization, and analytics can dramatically improve cell growth, productivity, and product quality for complex processes.
-
![Scientists working in lab-GettyImages-542935478]( "Cell Culture Media Mixing In A Benchtop Single-Use Mixer")
Cell Culture Media Mixing In A Benchtop Single-Use MixerExplore how efficient powder-liquid mixing and sterile filtration preserve media integrity and support reproducibility in biopharmaceutical workflows, with promising scalability for larger-volume applications.
-
![Assessing Particle Generation In A Single-Use Mixing System]( "Assessing Particle Generation In A Single-Use Mixing System")
Assessing Particle Generation In A Single-Use Mixing SystemExplore how particle levels remained stable during 24 hours of high-speed mixing, even under extreme temperatures, confirming a system’s suitability for final fill and other particulate-sensitive applications.
ABOUT BIOSIMILAR MANUFACTURING
Biosimilars are considered to be low-cost substitutions for pricy, large-molecule biologics. However, biosimilars must meet the same quality, safety, and efficacy as their reference biologic. Manufacturing biosimilars requires a more complicated procedure than that of manufacturing small molecule generics. Companies manufacturing biosimilars are focused on creating a chemical structure that is as close as possible to that of the reference product. Failure rates and operational costs pose a challenge for those companies involved in manufacturing biosimilars compared to those manufacturing small molecule generics.
Small molecule generics are created using the same active pharmaceutical ingredient (API) and, therefore, are chemically identical to that of the originator medicine. The manufacturing process for small molecules comprises only one-fifth of the total in-process tests required to meet Good Manufacturing Practice compared to that of biologic medicines (50 vs. 250 in-process tests). In fact, the manufacturing process for a large molecule is so complex, it cannot be duplicated by two different manufacturers, as the cells used in biologic medicines are unique to the company manufacturing each biologic.
Manufacturing a biologic consists of genetically modifying a cell, which becomes the basis for a cell line used for the production of the necessary protein for the biologic medicine. The protein is then separated from the cells and purified. Biosimilars are created from small alterations to the manufacturing process which creates a molecule that is not identical but closely resembles the reference product. While the differences in the biosimilar molecule might be slight, these changes in the manufacturing process of a biosimilar can affect the efficacy and safety of a biosimilar compared to the reference biologic. Over the past decade, the manufacturing process for proteins has become more standardized and the required technology has become increasingly accessible, leading to reductions in biosimilars production costs. As a result, a greater number of companies have begun manufacturing biosimilars, while reference brand manufacturers are setting their sights on bolstering pipelines and manufacturing biobetters to maintain market share for their soon-to-be-off-patent reference products.
BIOSIMILAR DEVELOPMENT NEWS
- Lupin And Valorum Enter Into An Exclusive Licensing Agreement For Biosimilar Armlupeg (Pegfilgrastim-unne) In The United States
- Mexico Will Receive New Biosimilars For Bone Health Through Saya Biologics In Collaboration With Enzene, A CDMO partner
- Formycon And MS Pharma Sign Exclusive Commercialization Partnership For Keytruda® Biosimilar Candidate FYB206 For The MENA Region
- mAbxience And HP Drive The Use Of Artificial Intelligence In Biomanufacturing And Biosimilar Development
- Biocon Biologics Secures Market Entry Date For Denosumab Biosimilars In Europe And Rest Of The World